Claim
Strong Support
causal

For healthy adults who have trouble falling asleep or staying asleep, taking 600 mg of Ashwagandha root extract and 3 mg of melatonin daily for two months helps them fall asleep faster, sleep longer, and spend more time in deep sleep compared to taking either supplement alone or a placebo.

85
Pro
0
Against

Evidence from Studies

No evidence studies found yet.

What Would Prove This

Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.

1
Systematic Reviews & Meta-Analyses

Whether the combination of Ashwagandha and melatonin consistently improves sleep onset latency, total sleep time, and sleep efficiency across diverse adult populations with mild-to-moderate sleep disturbance, accounting for variations in dosage, formulation, and duration.

A systematic review and meta-analysis of at least 10 high-quality RCTs (n≥500 total participants) comparing Ashwagandha (300–600 mg/day) plus melatonin (1–5 mg/day) versus placebo or monotherapy in adults aged 18–60 with DSM-5-defined sleep disturbance, using actigraphy for primary outcomes, with follow-up ≥8 weeks, and reporting standardized effect sizes for SOL, TST, and SE.

2
Randomized Controlled Trials
In Evidence

That the combination of Ashwagandha and melatonin causally improves sleep parameters in a broader, more diverse population, including those with comorbid anxiety or mild insomnia, and confirms durability of effect beyond eight weeks.

A multicenter, double-blind, placebo-controlled RCT with 400 participants aged 18–60, randomized to Ashwagandha (600 mg/day) + melatonin (3 mg/day), Ashwagandha alone, melatonin alone, or placebo, for 16 weeks, with primary outcomes measured by actigraphy (SOL, TST, SE) and secondary outcomes including PSQI, HAM-A, and cortisol levels, with follow-up at 24 weeks.

3
Cohort Studies

Whether long-term use of Ashwagandha and melatonin in real-world settings is associated with sustained improvements in sleep quality and reduced reliance on sleep medications over 1–3 years.

A prospective cohort study following 1,000 adults aged 18–60 with mild sleep disturbance who choose to take Ashwagandha (600 mg/day) and melatonin (3 mg/day) daily versus those who do not, tracking sleep quality (actigraphy and PSQI), anxiety (HAM-A), and medication use annually for three years, adjusting for lifestyle, stress, and comorbidities.

4
Case-Control Studies

Whether individuals who experience persistent sleep improvement after using Ashwagandha and melatonin differ in genetic, metabolic, or neuroendocrine profiles from those who do not respond.

A case-control study comparing 100 responders (≥20% improvement in SOL and SE after 8 weeks of Ashwagandha + melatonin) with 100 non-responders, matched for age, sex, and baseline sleep severity, analyzing serum cortisol, GABA metabolites, melatonin receptor polymorphisms, and inflammatory markers.

5
Cross-Sectional Studies

The prevalence of sleep improvement among adults currently using Ashwagandha and melatonin in the general population, and its association with self-reported sleep quality.

A national survey of 5,000 adults aged 18–60 assessing current use of Ashwagandha and melatonin supplements, sleep duration, latency, and quality via validated questionnaires, with adjustment for age, BMI, caffeine, and screen time.

Sign up to see full verdict